Dexamethasone
- Generic Name
- Dexamethasone
- Brand Names
- Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29FO5
- CAS Number
- 50-02-2
- Unique Ingredient Identifier
- 7S5I7G3JQL
- Background
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
- Indication
Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.
- Associated Conditions
- Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes
- Associated Therapies
- -
First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade
- Conditions
- Multiple Myeloma
- Interventions
- Drug: VELCADEDrug: DVT prophylaxisDrug: LenalidomideDrug: Liposomal doxorubicinDrug: DexamethasoneDrug: Bisphosphonates
- First Posted Date
- 2010-10-06
- Last Posted Date
- 2018-05-15
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT01215344
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸University of Tennessee Cancer Institute, Boston Baskin Cancer Group, Memphis, Tennessee, United States
Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Refractory Multiple Myeloma
- Interventions
- Drug: pomalidomideDrug: bortezomibDrug: dexamethasoneOther: laboratory biomarker analysisOther: gene expression analysis
- First Posted Date
- 2010-10-01
- Last Posted Date
- 2020-04-17
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 50
- Registration Number
- NCT01212952
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
Topical Cyclosporine for Vernal Keratoconjunctivitis (VKC) in Rwanda
- Conditions
- Vernal Keratoconjunctivitis
- Interventions
- First Posted Date
- 2010-09-29
- Last Posted Date
- 2010-09-29
- Lead Sponsor
- University Hospital, Ghent
- Target Recruit Count
- 366
- Registration Number
- NCT01211327
- Locations
- 🇷🇼
Kabgayi Hospital, Gitarama/Muhanga, Rwanda
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2010-09-24
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Paul Richardson, MD
- Target Recruit Count
- 729
- Registration Number
- NCT01208662
- Locations
- 🇺🇸
Newton-Wellesley Hospital, Newton, Massachusetts, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸Arizona Comprehensive Cancer Center, Tucson, Arizona, United States
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
- Conditions
- Blast CrisisAMLMultiple MyelomaALLMDS
- Interventions
- First Posted Date
- 2010-09-17
- Last Posted Date
- 2016-05-06
- Lead Sponsor
- Tragara Pharmaceuticals, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT01204164
- Locations
- 🇺🇸
MDACC, Houston, Texas, United States
🇺🇸RMCC, Denver, Colorado, United States
🇺🇸Cornell, New York City, New York, United States
The Effect of Peritonsillar Infiltration of Ketamine and Dexamethasone for Postoperative Pain Relief in Children Following Adenotonsillectomy
- Conditions
- Tonsillectomy
- Interventions
- First Posted Date
- 2010-09-10
- Last Posted Date
- 2013-05-07
- Lead Sponsor
- Qazvin University Of Medical Sciences
- Target Recruit Count
- 160
- Registration Number
- NCT01198210
- Locations
- 🇮🇷
Qazvin university of medical science, Qazvin, Iran, Islamic Republic of
Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed
- Conditions
- Primary Systemic Amyloidosis
- Interventions
- First Posted Date
- 2010-09-03
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 30
- Registration Number
- NCT01194791
- Locations
- 🇪🇸
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
🇪🇸Hospital Clínico San Carlos, Madrid, Spain
🇪🇸Hospital Lozano Blesa, Zaragoza, Spain
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
- Conditions
- Ann Arbor Stage I B Lymphoblastic LymphomaChildhood B Acute Lymphoblastic LeukemiaAcute Lymphoblastic LeukemiaAdult B Lymphoblastic LymphomaChildhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Down SyndromeHypodiploid B Acute Lymphoblastic LeukemiaPhiladelphia Chromosome PositiveAnn Arbor Stage II B Lymphoblastic LymphomaChildhood B Lymphoblastic Lymphoma
- Interventions
- Drug: DexamethasoneDrug: CyclophosphamideDrug: CytarabineDrug: MercaptopurineDrug: MethotrexateDrug: Doxorubicin HydrochlorideOther: Quality-of-Life AssessmentOther: Laboratory Biomarker AnalysisOther: Questionnaire AdministrationDrug: Leucovorin CalciumDrug: Vincristine SulfateDrug: PegaspargaseDrug: Thioguanine
- First Posted Date
- 2010-08-30
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 9350
- Registration Number
- NCT01190930
- Locations
- 🇺🇸
Valley Children's Hospital, Madera, California, United States
🇺🇸University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Preoperative Single-dose Steroid Application for the Treatment of Nausea and Vomiting After Thyroid Surgery
- Conditions
- ThyroidectomyThyroid Diseases
- Interventions
- Other: NaCl 0.9%Drug: Dexamethasone
- First Posted Date
- 2010-08-26
- Last Posted Date
- 2015-07-07
- Lead Sponsor
- Cantonal Hospital of St. Gallen
- Target Recruit Count
- 152
- Registration Number
- NCT01189292
- Locations
- 🇨🇭
Department of Surgery, St. Gallen, Switzerland
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2010-08-25
- Last Posted Date
- 2016-10-14
- Lead Sponsor
- Achieve Life Sciences
- Target Recruit Count
- 1022
- Registration Number
- NCT01188187
- Locations
- 🇳🇱
Teva Investigational Site 852, Rotterdam, Netherlands
🇺🇸Teva Investigational Site 093, Marina del Rey, California, United States
🇺🇸Teva Investigational Site 100, Birmingham, Alabama, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.